Matisse Pharmaceuticals B.V.
Matisse Pharmaceuticals B.V. is a biopharmaceutical clinical stage company based in Geleen, The Netherlands. Founded in 2014, the company is dedicated to developing innovative therapies targeting life-threatening inflammation, particularly in sepsis and septic shock. Their mission is to save millions of lives by effectively neutralizing extracellular cytotoxic histones, with a vision to become the first company worldwide to effectively combat sepsis.
Industries
N/A
Nr. of Employees
small (1-50)
Matisse Pharmaceuticals B.V.
Products
Anionic low-anticoagulant heparin-derived therapeutic candidate for neutralizing extracellular histones
An intravenously administered, highly anionic fraction derived from unfractionated heparin developed to irreversibly bind and neutralize extracellular cationic histones implicated in endothelial damage during sepsis; demonstrated in vitro neutralization and efficacy in multiple animal sepsis models and advanced to Phase I/IIa clinical development.
Next-generation anionic heparin-derived molecule program
Development program for next-generation molecules derived from the same platform with modified mechanism of action intended to broaden therapeutic scope and improve properties over the initial candidate.
Anionic low-anticoagulant heparin-derived therapeutic candidate for neutralizing extracellular histones
An intravenously administered, highly anionic fraction derived from unfractionated heparin developed to irreversibly bind and neutralize extracellular cationic histones implicated in endothelial damage during sepsis; demonstrated in vitro neutralization and efficacy in multiple animal sepsis models and advanced to Phase I/IIa clinical development.
Next-generation anionic heparin-derived molecule program
Development program for next-generation molecules derived from the same platform with modified mechanism of action intended to broaden therapeutic scope and improve properties over the initial candidate.
Services
Negotiation and management of research and commercialization licenses with academic institutions and initiation of strategic collaborations with medical centers and contract providers.
Operational management and oversight of Phase I/IIa clinical studies in sepsis, including protocol development, site coordination at university hospitals, and safety/PK/PD monitoring.
Negotiation and management of research and commercialization licenses with academic institutions and initiation of strategic collaborations with medical centers and contract providers.
Operational management and oversight of Phase I/IIa clinical studies in sepsis, including protocol development, site coordination at university hospitals, and safety/PK/PD monitoring.
Expertise Areas
- Sepsis therapeutics development
- Early-phase clinical trial management in critical care/ICU
- Biomarker-driven PK/PD evaluation
- Heparin-derived molecule fractionation and formulation
Key Technologies
- Affinity chromatography for molecular fractionation
- GMP parenteral manufacturing
- Biomarker assays for plasma histone H3 and CRP
- PK/PD analysis for intravenous therapeutics
News & Updates
Matisse Pharmaceuticals received approval from the German Regulatory Authorities to start a phase 1 study evaluating the safety, tolerability, and pharmacokinetics of a prolonged intravenous infusion with its lead compound M6229.
Prof. Carolyn Calfee, an expert in critical care and respiratory infections, joins the Scientific Advisory Board of Matisse Pharmaceuticals.
Matisse Pharmaceuticals received approval from the German Regulatory Authorities to start a phase 1 study evaluating the safety, tolerability, and pharmacokinetics of a prolonged intravenous infusion with its lead compound M6229.
Prof. Carolyn Calfee, an expert in critical care and respiratory infections, joins the Scientific Advisory Board of Matisse Pharmaceuticals.